Rüdiger Hehlmann

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

Andreas Hochhaus, Sebastian Kreil, A. Corbin et al. · Leukemia · 2002 · 900 citations

Chromatin, Genome Instability, Cell Division +9

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

Tiziano Barbui, Giovanni Barosi, Gunnar Birgegård et al. · Journal of Clinical Oncology · 2011 · 825 citations · Full text

Mixed-phenotype Acute Leukemia, European Leukemianet, Pathology +16

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

Joerg Hasford, Michele Baccarani, Verena Hoffmann et al. · Blood · 2011 · 492 citations · Full text

Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group [see comments]

Rüdiger Hehlmann, H. Heimpel, Joerg Hasford et al. · Blood · 1994 · 456 citations · Full text

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

Benjamin Hanfstein, Marc Müller, Rüdiger Hehlmann et al. · Leukemia · 2012 · 416 citations

Hematological Malignancy, Chronic Myeloid Leukemia, Health Sciences +10